1. PREDICTED RESPONSE RATE AND ALL PAIRWISE RISK RATIO
   1. At 8 weeks

Table S1: Predicted response rate for all treatment

|  |  |  |  |
| --- | --- | --- | --- |
| Treatment | **PASI50**  Mean [95% CI] | **PASI75**  Mean [95% CI] | **PASI90**  Mean [95% CI] |
| Secukinumab 300 mg | 0.924 [0.891,0.951] | 0.752 [0.686,0.816] | 0.463 [0.385,0.548] |
| Infliximab 5 mg | 0.913 [0.871,0.947] | 0.728 [0.647,0.806] | 0.435 [0.344,0.534] |
| Secukinumab 150 mg | 0.848 [0.797,0.894] | 0.609 [0.533,0.687] | 0.31 [0.243,0.386] |
| Adalimumab 40 mg | 0.76 [0.7,0.812] | 0.482 [0.41,0.551] | 0.206 [0.157,0.259] |
| Placebo | 0.12 [0.095,0.145] | 0.027 [0.02,0.034] | 0.003 [0.002,0.005] |

Table S2: All pairwise risk ratio for PASI 50

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Placebo  Mean RR [95% CI] | Adalimumab 40 mg  Mean RR [95% CI] | Infliximab 5 mg  Mean RR [95% CI] | Secukinumab 150 mg  Mean RR [95% CI] | Secukinumab 300 mg  Mean RR [95% CI] |
| Placebo | 1 (1, 1) | 0.16 (0.12, 0.19) | 0.13 (0.1, 0.16) | 0.14 (0.11, 0.17) | 0.13 (0.1, 0.16) |
| Adalimumab 40 mg | 6.4 (5.24, 8.01) | 1 (1, 1) | 0.83 (0.75, 0.91) | 0.9 (0.81, 0.98) | 0.82 (0.75, 0.89) |
| Infliximab 5 mg | 7.69 (6.27, 9.64) | 1.2 (1.1, 1.32) | 1 (1, 1) | 1.08 (1, 1.16) | 0.99 (0.93, 1.05) |
| Secukinumab 150 mg | 7.14 (5.94, 8.76) | 1.12 (1.02, 1.23) | 0.93 (0.86, 1) | 1 (1, 1) | 0.92 (0.88, 0.95) |
| Secukinumab 300 mg | 7.78 (6.44, 9.58) | 1.22 (1.13, 1.33) | 1.01 (0.96, 1.07) | 1.09 (1.05, 1.14) | 1 (1, 1) |

Table S3: All pairwise risk ratio for PASI 75

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Placebo  Mean RR [95% CI] | Adalimumab 40 mg  Mean RR [95% CI] | Infliximab 5 mg  Mean RR [95% CI] | Secukinumab 150 mg  Mean RR [95% CI] | Secukinumab 300 mg  Mean RR [95% CI] |
| Placebo | 1 (1, 1) | 0.06 (0.04, 0.07) | 0.04 (0.03, 0.05) | 0.04 (0.03, 0.06) | 0.04 (0.03, 0.05) |
| Adalimumab 40 mg | 18.28 (13.67, 25.1) | 1 (1, 1) | 0.66 (0.53, 0.8) | 0.79 (0.64, 0.96) | 0.64 (0.53, 0.75) |
| Infliximab 5 mg | 27.67 (20.54, 37.81) | 1.52 (1.25, 1.87) | 1 (1, 1) | 1.2 (1, 1.44) | 0.97 (0.83, 1.13) |
| Secukinumab 150 mg | 23.05 (17.86, 30.25) | 1.27 (1.04, 1.56) | 0.84 (0.69, 1) | 1 (1, 1) | 0.81 (0.74, 0.88) |
| Secukinumab 300 mg | 28.48 (22.1, 37.37) | 1.57 (1.32, 1.89) | 1.04 (0.89, 1.21) | 1.24 (1.14, 1.35) | 1 (1, 1) |

Table S4: All pairwise risk ratio for PASI 90

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Placebo  Mean RR [95% CI] | Adalimumab 40 mg  Mean RR [95% CI] | Infliximab 5 mg  Mean RR [95% CI] | Secukinumab 150 mg  Mean RR [95% CI] | Secukinumab 300 mg  Mean RR [95% CI] |
| Placebo | 1 (1, 1) | 0.02 (0.01, 0.02) | 0.01 (0, 0.01) | 0.01 (0.01, 0.02) | 0.01 (0, 0.01) |
| Adalimumab 40 mg | 62.42 (41.15, 96.23) | 1 (1, 1) | 0.48 (0.32, 0.67) | 0.68 (0.46, 0.93) | 0.45 (0.32, 0.6) |
| Infliximab 5 mg | 132.18 (85, 204.9) | 2.15 (1.48, 3.09) | 1 (1, 1) | 1.43 (1, 2) | 0.95 (0.68, 1.28) |
| Secukinumab 150 mg | 93.24 (65.08, 134.9) | 1.53 (1.08, 2.17) | 0.72 (0.5, 1) | 1 (1, 1) | 0.67 (0.57, 0.77) |
| Secukinumab 300 mg | 139.57 (98.36, 200) | 2.28 (1.68, 3.15) | 1.08 (0.78, 1.46) | 1.5 (1.29, 1.76) | 1 (1, 1) |

* 1. At 12 weeks

Table S5: Predicted response rate for all treatment

|  |  |  |  |
| --- | --- | --- | --- |
| Treatment | **PASI50**  Mean [95% CI] | **PASI75**  Mean [95% CI] | **PASI90**  Mean [95% CI] |
| Secukinumab 300 mg | 0.94 [0.912,0.964] | 0.851 [0.8,0.899] | 0.621 [0.542,0.705] |
| Infliximab 5 mg | 0.935 [0.876,0.973] | 0.841 [0.736,0.919] | 0.609 [0.459,0.746] |
| Secukinumab 150 mg | 0.881 [0.833,0.923] | 0.746 [0.674,0.816] | 0.472 [0.388,0.566] |
| Adalimumab 40 mg | 0.803 [0.742,0.854] | 0.631 [0.552,0.702] | 0.345 [0.272,0.418] |
| Placebo | 0.119 [0.095,0.143] | 0.044 [0.034,0.056] | 0.007 [0.005,0.01] |

Table S6: All pairwise risk ratio for PASI 50

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Placebo  Mean RR [95% CI] | Adalimumab 40 mg  Mean RR [95% CI] | Infliximab 5 mg  Mean RR [95% CI] | Secukinumab 150 mg  Mean RR [95% CI] | Secukinumab 300 mg  Mean RR [95% CI] |
| Placebo | 1 (1, 1) | 0.15 (0.12, 0.18) | 0.13 (0.1, 0.15) | 0.13 (0.11, 0.16) | 0.13 (0.1, 0.15) |
| Adalimumab 40 mg | 6.84 (5.62, 8.46) | 1 (1, 1) | 0.86 (0.78, 0.95) | 0.91 (0.83, 0.99) | 0.85 (0.78, 0.92) |
| Infliximab 5 mg | 7.97 (6.46, 9.99) | 1.17 (1.06, 1.28) | 1 (1, 1) | 1.06 (0.97, 1.14) | 0.99 (0.92, 1.05) |
| Secukinumab 150 mg | 7.51 (6.18, 9.22) | 1.1 (1.01, 1.21) | 0.94 (0.87, 1.03) | 1 (1, 1) | 0.94 (0.9, 0.97) |
| Secukinumab 300 mg | 8.02 (6.6, 9.85) | 1.17 (1.09, 1.28) | 1.01 (0.95, 1.08) | 1.07 (1.03, 1.11) | 1 (1, 1) |

Table S7: All pairwise risk ratio for PASI 75

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Placebo  Mean RR [95% CI] | Adalimumab 40 mg  Mean RR [95% CI] | Infliximab 5 mg  Mean RR [95% CI] | Secukinumab 150 mg  Mean RR [95% CI] | Secukinumab 300 mg  Mean RR [95% CI] |
| Placebo | 1 (1, 1) | 0.07 (0.05, 0.09) | 0.05 (0.04, 0.07) | 0.06 (0.05, 0.08) | 0.05 (0.04, 0.07) |
| Adalimumab 40 mg | 14.44 (11.2, 18.95) | 1 (1, 1) | 0.75 (0.63, 0.9) | 0.85 (0.71, 0.99) | 0.74 (0.64, 0.84) |
| Infliximab 5 mg | 19.3 (14.52, 25.91) | 1.34 (1.11, 1.59) | 1 (1, 1) | 1.13 (0.95, 1.31) | 0.99 (0.85, 1.11) |
| Secukinumab 150 mg | 17.08 (13.29, 22.22) | 1.19 (1.01, 1.4) | 0.89 (0.77, 1.05) | 1 (1, 1) | 0.88 (0.81, 0.94) |
| Secukinumab 300 mg | 19.49 (15.24, 25.2) | 1.35 (1.19, 1.57) | 1.01 (0.9, 1.18) | 1.14 (1.06, 1.23) | 1 (1, 1) |

Table S8: All pairwise risk ratio for PASI 90

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Placebo  Mean RR [95% CI] | Adalimumab 40 mg  Mean RR [95% CI] | Infliximab 5 mg  Mean RR [95% CI] | Secukinumab 150 mg  Mean RR [95% CI] | Secukinumab 300 mg  Mean RR [95% CI] |
| Placebo | 1 (1, 1) | 0.02 (0.01, 0.03) | 0.01 (0.01, 0.02) | 0.02 (0.01, 0.02) | 0.01 (0.01, 0.02) |
| Adalimumab 40 mg | 47.86 (33.17, 69.65) | 1 (1, 1) | 0.58 (0.4, 0.82) | 0.74 (0.53, 0.97) | 0.56 (0.42, 0.71) |
| Infliximab 5 mg | 84.98 (54.14, 131.3) | 1.79 (1.22, 2.5) | 1 (1, 1) | 1.3 (0.9, 1.75) | 0.99 (0.7, 1.27) |
| Secukinumab 150 mg | 65.54 (45.61, 94.31) | 1.39 (1.03, 1.88) | 0.79 (0.57, 1.11) | 1 (1, 1) | 0.76 (0.65, 0.87) |
| Secukinumab 300 mg | 86.25 (60.85, 122.3) | 1.82 (1.41, 2.4) | 1.04 (0.78, 1.42) | 1.32 (1.15, 1.53) | 1 (1, 1) |

* 1. At 16 weeks

Table S9: Predicted response rate for all treatment

|  |  |  |  |
| --- | --- | --- | --- |
| Treatment | **PASI50**  Mean [95% CI] | **PASI75**  Mean [95% CI] | **PASI90**  Mean [95% CI] |
| Secukinumab 300 mg | 0.976 [0.96,0.989] | 0.935 [0.899,0.964] | 0.805 [0.732,0.874] |
| Infliximab 5 mg | 0.942 [0.909,0.969] | 0.865 [0.806,0.917] | 0.674 [0.582,0.767] |
| Secukinumab 150 mg | 0.894 [0.827,0.948] | 0.783 [0.681,0.875] | 0.554 [0.426,0.688] |
| Adalimumab 40 mg | 0.825 [0.757,0.875] | 0.679 [0.59,0.751] | 0.425 [0.333,0.508] |
| Placebo | 0.15 [0.124,0.178] | 0.066 [0.052,0.081] | 0.015 [0.011,0.02] |

Table S10: All pairwise risk ratio for PASI 50

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Placebo  Mean RR [95% CI] | Adalimumab 40 mg  Mean RR [95% CI] | Infliximab 5 mg  Mean RR [95% CI] | Secukinumab 150 mg  Mean RR [95% CI] | Secukinumab 300 mg  Mean RR [95% CI] |
| Placebo | 1 (1, 1) | 0.18 (0.15, 0.22) | 0.17 (0.14, 0.2) | 0.16 (0.13, 0.19) | 0.15 (0.13, 0.18) |
| Adalimumab 40 mg | 5.54 (4.61, 6.65) | 1 (1, 1) | 0.92 (0.83, 1.02) | 0.88 (0.8, 0.94) | 0.85 (0.77, 0.9) |
| Infliximab 5 mg | 6.01 (4.93, 7.33) | 1.09 (0.98, 1.21) | 1 (1, 1) | 0.95 (0.87, 1.02) | 0.92 (0.84, 0.97) |
| Secukinumab 150 mg | 6.33 (5.29, 7.58) | 1.14 (1.06, 1.25) | 1.05 (0.98, 1.15) | 1 (1, 1) | 0.97 (0.94, 0.99) |
| Secukinumab 300 mg | 6.56 (5.49, 7.86) | 1.18 (1.11, 1.29) | 1.09 (1.03, 1.18) | 1.04 (1.01, 1.07) | 1 (1, 1) |

Table S11: All pairwise risk ratio for PASI 75

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Placebo  Mean RR [95% CI] | Adalimumab 40 mg  Mean RR [95% CI] | Infliximab 5 mg  Mean RR [95% CI] | Secukinumab 150 mg  Mean RR [95% CI] | Secukinumab 300 mg  Mean RR [95% CI] |
| Placebo | 1 (1, 1) | 0.1 (0.08, 0.12) | 0.08 (0.06, 0.11) | 0.08 (0.06, 0.09) | 0.07 (0.06, 0.09) |
| Adalimumab 40 mg | 10.47 (8.18, 13.21) | 1 (1, 1) | 0.87 (0.72, 1.03) | 0.79 (0.67, 0.89) | 0.73 (0.63, 0.81) |
| Infliximab 5 mg | 12.1 (9.24, 15.72) | 1.16 (0.97, 1.39) | 1 (1, 1) | 0.91 (0.77, 1.04) | 0.84 (0.72, 0.94) |
| Secukinumab 150 mg | 13.35 (10.66, 16.71) | 1.28 (1.12, 1.5) | 1.11 (0.96, 1.29) | 1 (1, 1) | 0.93 (0.88, 0.97) |
| Secukinumab 300 mg | 14.43 (11.54, 17.99) | 1.38 (1.23, 1.6) | 1.2 (1.06, 1.38) | 1.08 (1.03, 1.14) | 1 (1, 1) |

Table S12: All pairwise risk ratio for PASI 90

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Placebo  Mean RR [95% CI] | Adalimumab 40 mg  Mean RR [95% CI] | Infliximab 5 mg  Mean RR [95% CI] | Secukinumab 150 mg  Mean RR [95% CI] | Secukinumab 300 mg  Mean RR [95% CI] |
| Placebo | 1 (1, 1) | 0.04 (0.03, 0.05) | 0.03 (0.02, 0.04) | 0.02 (0.02, 0.03) | 0.02 (0.01, 0.03) |
| Adalimumab 40 mg | 28.62 (19.98, 39.4) | 1 (1, 1) | 0.78 (0.55, 1.06) | 0.63 (0.47, 0.8) | 0.53 (0.4, 0.65) |
| Infliximab 5 mg | 37.42 (24.83, 54.98) | 1.32 (0.95, 1.83) | 1 (1, 1) | 0.83 (0.6, 1.08) | 0.69 (0.52, 0.88) |
| Secukinumab 150 mg | 45.44 (32.94, 62.1) | 1.61 (1.25, 2.12) | 1.24 (0.92, 1.66) | 1 (1, 1) | 0.84 (0.75, 0.93) |
| Secukinumab 300 mg | 54.28 (39.96, 73.22) | 1.92 (1.54, 2.48) | 1.48 (1.14, 1.94) | 1.2 (1.08, 1.34) | 1 (1, 1) |

* 1. At 24 weeks

Table S13: Predicted response rate for all treatment

|  |  |  |  |
| --- | --- | --- | --- |
| Treatment | **PASI50**  Mean [95% CI] | **PASI75**  Mean [95% CI] | **PASI90**  Mean [95% CI] |
| Secukinumab 300 mg | 0.971 [0.928,0.993] | 0.923 [0.838,0.976] | 0.815 [0.67,0.923] |
| Infliximab 5 mg | 0.927 [0.842,0.977] | 0.839 [0.701,0.936] | 0.676 [0.492,0.835] |
| Secukinumab 150 mg | 0.827 [0.616,0.953] | 0.687 [0.428,0.883] | 0.488 [0.232,0.74] |
| Adalimumab 40 mg | 0.783 [0.516,0.952] | 0.632 [0.33,0.881] | 0.433 [0.163,0.737] |
| Placebo | 0.136 [0.107,0.167] | 0.058 [0.043,0.074] | 0.017 [0.012,0.023] |

Table S14: All pairwise risk ratio for PASI 50

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Placebo  Mean RR [95% CI] | Adalimumab 40 mg  Mean RR [95% CI] | Infliximab 5 mg  Mean RR [95% CI] | Secukinumab 150 mg  Mean RR [95% CI] | Secukinumab 300 mg  Mean RR [95% CI] |
| Placebo | 1 (1, 1) | 0.17 (0.12, 0.23) | 0.18 (0.12, 0.27) | 0.15 (0.12, 0.18) | 0.14 (0.11, 0.17) |
| Adalimumab 40 mg | 6.15 (4.26, 8.18) | 1 (1, 1) | 1.09 (0.73, 1.64) | 0.89 (0.66, 1.06) | 0.85 (0.63, 0.99) |
| Infliximab 5 mg | 5.83 (3.66, 8.01) | 0.96 (0.61, 1.37) | 1 (1, 1) | 0.85 (0.55, 1.05) | 0.81 (0.53, 0.99) |
| Secukinumab 150 mg | 6.89 (5.5, 8.68) | 1.14 (0.94, 1.52) | 1.22 (0.95, 1.81) | 1 (1, 1) | 0.95 (0.88, 1) |
| Secukinumab 300 mg | 7.21 (5.81, 9.06) | 1.19 (1.01, 1.58) | 1.27 (1.01, 1.89) | 1.05 (1, 1.13) | 1 (1, 1) |

Table S15: All pairwise risk ratio for PASI 75

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Placebo  Mean RR [95% CI] | Adalimumab 40 mg  Mean RR [95% CI] | Infliximab 5 mg  Mean RR [95% CI] | Secukinumab 150 mg  Mean RR [95% CI] | Secukinumab 300 mg  Mean RR [95% CI] |
| Placebo | 1 (1, 1) | 0.09 (0.06, 0.14) | 0.1 (0.06, 0.18) | 0.07 (0.05, 0.09) | 0.06 (0.05, 0.08) |
| Adalimumab 40 mg | 12.2 (6.98, 18.18) | 1 (1, 1) | 1.17 (0.6, 2.19) | 0.82 (0.5, 1.12) | 0.75 (0.46, 0.98) |
| Infliximab 5 mg | 11.22 (5.55, 17.61) | 0.96 (0.46, 1.68) | 1 (1, 1) | 0.76 (0.39, 1.1) | 0.69 (0.36, 0.97) |
| Secukinumab 150 mg | 14.85 (10.91, 20.03) | 1.27 (0.89, 2.01) | 1.42 (0.91, 2.57) | 1 (1, 1) | 0.91 (0.79, 1) |
| Secukinumab 300 mg | 16.36 (12.36, 21.74) | 1.39 (1.02, 2.18) | 1.56 (1.03, 2.82) | 1.11 (1, 1.27) | 1 (1, 1) |

Table S16: All pairwise risk ratio for PASI 90

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Placebo  Mean RR [95% CI] | Adalimumab 40 mg  Mean RR [95% CI] | Infliximab 5 mg  Mean RR [95% CI] | Secukinumab 150 mg  Mean RR [95% CI] | Secukinumab 300 mg  Mean RR [95% CI] |
| Placebo | 1 (1, 1) | 0.04 (0.02, 0.08) | 0.05 (0.02, 0.11) | 0.03 (0.02, 0.04) | 0.02 (0.01, 0.03) |
| Adalimumab 40 mg | 29.83 (12.89, 52.6) | 1 (1, 1) | 1.33 (0.44, 3.28) | 0.74 (0.33, 1.23) | 0.6 (0.28, 0.96) |
| Infliximab 5 mg | 26.4 (9.3, 50.15) | 0.98 (0.31, 2.26) | 1 (1, 1) | 0.65 (0.23, 1.19) | 0.54 (0.2, 0.94) |
| Secukinumab 150 mg | 41.09 (26.25, 61.41) | 1.52 (0.81, 3.05) | 1.84 (0.84, 4.32) | 1 (1, 1) | 0.83 (0.64, 1) |
| Secukinumab 300 mg | 49.55 (33.66, 71.51) | 1.83 (1.05, 3.59) | 2.21 (1.07, 5.13) | 1.22 (1, 1.55) | 1 (1, 1) |